FDA Commissioner Marty Makary Faces Potential Dismissal

President Trump has reportedly signed off on a plan to dismiss Food and Drug Administration (FDA) Commissioner Marty Makary. According to STAT News, this move would be the latest high-profile departure within the health department led by Robert F. Kennedy Jr. While the news has spread quickly, sources caution that the plan is not yet final and could still change.

Makary has served as the head of the FDA for just over a year. His time in the role was ambitious, featuring many new projects. These included efforts to speed up the review process for new drugs, take action against misleading advertisements, and pressure the food industry to remove certain chemical dyes. However, his tenure has also been difficult, filled with personnel drama and the departure of many long-term staff members.

Reports from MedPage Today and Ars Technica highlight that Makary faced significant pressure from the White House and other health officials. A major point of conflict involved the approval of flavored vaping products. President Trump reportedly scolded Makary for not moving fast enough to approve these items, which the president had promised to support during his campaign. Makary had initially delayed the approval of flavors like menthol and mango due to concerns that they might attract young people to vaping. After facing pressure from the administration, the FDA finally authorized these products earlier this week.

Beyond the vaping issue, Makary faced other political challenges. STAT News noted that he angered some Republican lawmakers and anti-abortion groups by moving slowly on a safety study regarding the abortion pill mifepristone. Additionally, MedPage Today reported that administration officials became frustrated by ongoing complaints from the pharmaceutical industry. Some biotech companies, particularly those working on drugs for rare diseases, have also been critical of his leadership.

If Makary is removed, it will add to a growing list of leadership gaps within the health agencies overseen by Robert F. Kennedy Jr. Currently, the Centers for Disease Control and Prevention (CDC) is operating without a permanent director, and the position of surgeon general remains empty. Ars Technica reports that high-level leaders across the FDA, CDC, and the National Institutes of Health have left their roles in large numbers since the start of the Trump administration.

Filling these positions is not a simple task, as the appointment of a permanent FDA commissioner requires confirmation by the U.S. Senate. The agency is already struggling with many vacancies in its main divisions that regulate the biopharmaceutical industry. The Trump administration recently attempted to fix some of these issues by changing leadership in the Department of Health and Human Services, hoping to reduce dysfunction and focus on popular initiatives like healthier food.

Despite the rumors of his exit, Makary has remained quiet about his future. When asked by reporters from STAT News outside a conference recently about how long he planned to stay at the agency, he simply gave a thumbs up and said he was "feeling good." As of now, the White House and spokespeople for both Makary and Kennedy have not responded to requests for comment regarding the reported plans for his departure.